The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trialAdriaan A. Voors, Piotr Ponikowski, Michael Fu et al.|Nature Medicine|2022Cited by 889
Efficacy of telemedical interventional management in patients with heart failure (TIM-HF2): a randomised, controlled, parallel-group, unmasked trialFriedrich Koehler, Karl Stangl, Kerstin Koehler et al.|The Lancet|2018Cited by 734
Bromocriptine for the treatment of peripartum cardiomyopathy: a multicentre randomized studyDenise Hilfiker‐Kleiner, Johann Bauersachs, Dominik Berliner et al.|European Heart Journal|2017Cited by 334
Impact of empagliflozin on decongestion in acute heart failure: the EMPULSE trialJan Biegus, Piotr Ponikowski, Adriaan A. Voors et al.|European Heart Journal|2022Cited by 213
Effects of Empagliflozin on Symptoms, Physical Limitations, and Quality of Life in Patients Hospitalized for Acute Heart Failure: Results From the EMPULSE TrialMikhail Kosiborod, Adriaan A. Voors, Christiane E. Angermann et al.|Circulation|2022Cited by 142